



**Recommendation to the Nova Scotia Department of Health from Capital District  
Health Authority/Cancer Care Nova Scotia  
Guidelines for the Role of Bevacizumab (Avastin®) in Metastatic Colorectal  
Cancer (MCRC)**

**Eligibility Criteria / Approved Use:**

Bevacizumab combination therapy in patients who have documented evidence of locally advanced or MCRC, with an ECOG performance status 0-2 for whom a combination would be recommended, choose to receive systemic chemotherapy and meet the following criteria:

1. Bevacizumab in combination with **first or second line combination chemotherapy** including irinotecan/fluoropyrimidine-based regimens such as FOLFIRI or IFL or oxaliplatin/fluoropyrimidine-based regimens such as FOLFOX. The value of continuing bevacizumab in the second line (after receiving with first line chemotherapy) is not clear. In any one patient, only **one option as first or second line** combination therapy is approved at a maximum dose of 5 mg/kg every two weeks (or equivalent dose).
2. Bevacizumab may be considered in combination with single agent fluoropyrimidine therapy such as 5-FU/LV or capecitabine in selected cases.
3. Bevacizumab would **not** be used in combination in the third-line setting.
4. Bevacizumab would **not** be used as a single agent therapy for patients where chemotherapy cannot be given or as maintenance therapy following combination chemotherapy discontinuation.
5. Bevacizumab would **not** be used post curative resection of metastatic disease i.e. pseudo-adjuvant therapy.
6. There is currently no data to support the use of Bevacizumab in the adjuvant setting.